For nearly a decade, xCures has been wrestling with one of the most stubborn problems in medicine: the fact that a single cancer patient's story is almost never told in one place. It is scattered across thousands of labs, hospitals, imaging centers, and electronic medical record systems, arriving as faxes, PDFs, and unstructured documents that no clinician or algorithm can easily read. On June 24, 2026, the Oakland-based company announced it had raised $46 million in Series B financing to scale the AI platform it built to stitch those fragments back together.
The round, led by Innovius Capital with participation from iGrow, GKCC, Spring Mountain Capital, and existing investors, brings xCures' total funding to more than $76 million since its 2018 founding. According to reporting from Crunchbase News, the deal values the company at roughly $127 million post-money — more than double the valuation from its $25 million Series A, which closed in December 2023.
Turning Messy Records Into Decision-Ready Data
xCures calls its core product the Clinical Clarity Engine. The pitch is straightforward even if the engineering is not: pull a patient's records from wherever they live across the U.S. healthcare system, then use AI to structure that raw material into what the company calls "decision-ready data" — organized patient histories, evidence-grade data points, and checklists clinicians can actually act on. Crucially, every answer the Engine produces links back to its source document, an attempt to solve the trust problem that has dogged AI in clinical settings.
The scale is already substantial. xCures says it has processed more than 300 million medical records sourced from over 550,000 healthcare locations nationwide, supporting clinical decisions for millions of patients. The platform was, in the company's words, "built on almost a decade of work in the most complex area of medicine, oncology, and is now used across all clinical domains."
That oncology origin matters. Cancer care is the hardest version of the data problem — patients see multiple specialists, undergo genomic testing, cycle through lines of therapy, and generate enormous volumes of imaging and pathology. A complete, structured treatment journey is precisely what oncologists, diagnostics labs, and clinical trial sponsors need and rarely have.
"Healthcare has spent decades generating enormous amounts of patient data without a reliable way to make that information usable. We're changing that," said Mika Newton, CEO of xCures, in the company's announcement. "This financing allows us to accelerate product development, expand our team, and help more organizations turn fragmented records into information they can actually act on."
A Business Built on Cancer's Hardest Data Problem
The funding arrives on the back of sharp commercial growth. xCures grew from roughly $3 million to $10 million in annualized recurring revenue in 2025 and is targeting more than $20 million in 2026, according to Crunchbase News. The company serves 25 enterprise clients, a roster that includes recognizable names in cancer diagnostics and treatment such as Exact Sciences, Caris Life Sciences, and Novocure.
For its lead investor, the bet is essentially a bet on the data layer beneath every other healthcare AI ambition. "The promise of AI in healthcare depends on having accurate, complete, and trustworthy clinical data," said Stu Posluns, a partner at Innovius. "xCures has built by far the most compelling platform we've seen for turning fragmented medical records into actionable clinical intelligence."
That framing captures why investors are circling companies like xCures. The generative-AI wave has produced no shortage of clinical chatbots and documentation tools, but most of them are only as good as the records they ingest. If the underlying data is incomplete, duplicated, or trapped in image-only PDFs, even the most capable model will hallucinate or miss context. Companies that can reliably normalize messy real-world clinical data are positioning themselves as the picks-and-shovels suppliers of the healthcare AI boom — and oncology, with its density of structured genomic and treatment information, is the richest seam to mine.
There is a second business hiding inside the first. Structured, longitudinal records of how real cancer patients are actually treated and how they respond constitute real-world evidence — data that pharmaceutical companies, regulators, and trial designers increasingly want. xCures has built much of its history around generating real-world evidence and supporting decentralized trials, and the same engine that helps a clinician understand one patient can, in aggregate, help match patients to trials or measure how therapies perform outside the controlled confines of a study.
What to Watch
The questions now are about durability and trust. xCures is selling into a market crowded with health-data incumbents and a growing field of AI startups making similar claims, and its moat ultimately depends on whether its "evidence-grade" promise holds up under clinical and regulatory scrutiny. The company notes its Engine is HITRUST certified, a nod to the privacy and security stakes of moving hundreds of millions of patient records.
With fresh capital, a doubled valuation, and revenue on track to roughly double again in 2026, xCures has runway to expand beyond oncology and deepen its enterprise relationships. Whether it can convert that momentum into the default infrastructure layer for clinical data — the role it is plainly auditioning for — is the story to follow over the next year.
---
Sources: [xCures press release](https://xcures.com/series-b/); [Crunchbase News](https://news.crunchbase.com/venture/xcures-lands-seriesb-medical-records-ai/); [PR Newswire](https://www.prnewswire.com/news-releases/xcures-closes-46-million-series-b-financing-to-transform-fragmented-medical-records-into-decision-ready-data-through-its-clinical-clarity-engine-302809282.html); [MobiHealthNews](https://www.mobihealthnews.com/news/xcures-raises-46m-expand-ai-clinical-data-platform); [HIT Consultant](https://hitconsultant.net/2026/06/25/xcures-raises-46-million-series-b-clinical-data-ai/).
"Healthcare has spent decades generating enormous amounts of patient data without a reliable way to make that information usable. We're changing that."- Mika Newton, CEO, xCures